





Clinical Hematology

THEORY & PROCEDURES

FIFTH EDITION

Mary Louise Turgeon



Wolters Kluwer
Health

Lippincott
Williams & Wilkins

Clinical Hematology

Theory and Procedures

FIFTH EDITION

Mary L. Turgeon, EdD, MT(ASCP)

Clinical Laboratory Education Consultant

Mary L. Turgeon & Associates

Boston, Massachusetts & St. Petersburg, Florida

Clinical Adjunct Assistant Professor

Tufts University

School of Medicine

Boston, Massachusetts

Professor

College of Professional Studies

Northeastern University

Boston, Massachusetts

Professor

Physician Assistant Graduate Program

South University

Tampa, Florida



Wolters Kluwer | Lippincott Williams & Wilkins

Health

Philadelphia • Baltimore • New York • London
Buenos Aires • Hong Kong • Sydney • Tokyo

Acquisitions Editor: Peter Sabatini
Product Manager: Meredith L. Brittain
Marketing Manager: Allison Powell
Designer: Stephen Druding
Production Services: SPi Technologies

Fifth Edition

Copyright © 2012, 2005 by Lippincott Williams & Wilkins, a Wolters Kluwer business.

351 West Camden Street
Baltimore, MD 21201

Two Commerce Square
2001 Market Street
Philadelphia, PA 19103

All rights reserved. This book is protected by copyright. No part of this book may be reproduced or transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright. To request permission, please contact Lippincott Williams & Wilkins at 530 Walnut Street, Philadelphia, PA 19106, via email at permissions@lww.com, or via website at lww.com (products and services).

Printed in China

Library of Congress Cataloging-in-Publication Data

Turgeon, Mary Louise.

Clinical hematology : theory and procedures / Mary Louise Turgeon. — 5th ed.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-60831-076-0

1. Hematology. I. Title.

[DNLM: 1. Hematologic Diseases. 2. Hematology—methods. WH 100]

RB145.T79 2010

616.1'5—dc22

2010031295

DISCLAIMER

Care has been taken to confirm the accuracy of the information present and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of this information in a particular situation remains the professional responsibility of the practitioner; the clinical treatments described and recommended may not be considered absolute and universal recommendations.

The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with the current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in their clinical practice.

To purchase additional copies of this book, call our customer service department at (800) 638-3030 or fax orders to (301) 223-2320. International customers should call (301) 223-2300.

Visit Lippincott Williams & Wilkins on the Internet: <http://www.lww.com>. Lippincott Williams & Wilkins customer service representatives are available from 8:30 am to 6:00 pm, EST.

9 8 7 6 5 4 3 2 1

Namaste

*To my husband, Dick Mordaunt
May we continue to fulfill our dreams of
adventure and learning*

PREFACE

It is a pleasure to author the 5th edition of *Clinical Hematology*. Since the 1st edition was published in 1988, each edition has included exciting changes in clinical hematology and posed challenges to learn more and teach more in a fixed time frame. The 5th edition retains the pedagogy that set the standard for clinical laboratory science textbooks since it was introduced in the 1st edition. *Clinical Hematology* now features integrated four-color images, tables, and boxes throughout the book for ease of learning. New online ancillaries include PowerPoint presentations, a quiz bank for students, and more than 800 unique test questions for instructors (see Additional Resources, below, for more information).

Each chapter in this edition capitalizes on the strengths of previous editions; up-to-date information presented at conferences and published in the professional literature; and comments received from students, faculty, faculty reviewers, and working professionals from around the globe. *Clinical Hematology* has been classroom and laboratory “field tested” by medical laboratory technician (MLT) and medical laboratory science (MLS) students, instructors, and the author. Hands-on presentation of the information and techniques discussed in *Clinical Hematology* underscores the importance of clarity, conciseness, and continuity of information for the entry-level student. Sole authorship of this textbook ensures a smooth transition from chapter to chapter without unnecessary redundancy or changes in writing style.

THE AUDIENCE

Clinical Hematology, 5th edition, is primarily intended to fulfill the needs of medical laboratory science (MLS) and medical laboratory technician (MLT) students and faculty as a time-tested book. MLT students may omit some portions of the book depending on the length of the curriculum. Other health professionals can use the book as an instructional or reference guide.

WHAT IS NEW IN THIS EDITION

The 5th edition continues with the innovative expansion of exciting molecular discoveries that assumed importance in the 4th edition—for example, p53 function in DNA repair and mechanisms of apoptosis. The book includes knowledge recognized by the Nobel Prize in Physiology or Medicine in 2009 for discoveries of telomere structure and maintenance and covers other genetic irregularities relevant to the pathophysiology and treatment of hematologic disease—for example, genetic abnormalities leading to ribosome dysfunction in Diamond-Blackfan anemia and genetic abnormalities in Fanconi anemia. The expansion of

classifications found in the recent World Health Organization Classifications appears in this edition. The treatment of many hematology disorders, particularly effective therapy for chronic myelogenous leukemia and chronic lymphocytic leukemia, clearly focuses research on understanding the molecular aspects of diagnosis and treatment of many other blood disorders.

Numerous new discoveries associated with red blood cells have been reported since the 4th edition. New discoveries are related to diagnosis and treatment of hemoglobin defects—that is, hemoglobinopathies. This information has a direct application to the laboratory, where the importance of global population migration creates new or an increased number of patients with disorders that were not commonly seen in clinical hematology before. In addition, this book describes exciting discoveries in iron metabolism and the relationship of iron physiology to anemia of chronic disorders.

Beginning with the 1st edition of *Clinical Hematology*, safety has been an important consideration. The 5th edition covers the latest safety information associated with the importance of immune status—that is, screening and recommended vaccinations of employees, and proper removal of disposable gloves. ISO 15189, quality and preanalytical error management issues, and a Spanish-English Phlebotomy guide (see Appendix D) are also included. The newest specimen-related information in this edition includes additional types of evacuated tubes, environmental factors that influence evacuated tubes, order of draw of multiple evacuated tubes collection, and order of draw of capillary specimens.

Hematology instrumentation continues to expand the menu of available assays. This edition presents the latest comparative instrument product information for cell counting and identification, and blood coagulation testing. The manual procedures chapter (Chapter 26) has been streamlined, with older techniques moved to a web-based repository. The format of the procedures continues to comply with Clinical Laboratory Standards Institute (CLSI) standards. The 1st edition of this book was the first clinical laboratory science textbook to institute standardization of procedures using the CLSI protocol.

ORGANIZATIONAL PHILOSOPHY

The six-part organization of *Clinical Hematology* follows the original profile for a logical combination of textbook, cellular morphology atlas, and procedure manual. Part 1, The Principles of Hematology, discusses the newest fundamental concepts including safety, quality assessment, and specimen collection. Chapter 3, Molecular Genetics and Cellular Morphology, continues to be of extreme importance in understanding the pathophysiology and diagnosis of many

blood disorders and related therapy. The last chapter in this part, Chapter 4, presents the normal development of blood cells in humans. This is essential basic information.

Parts 2 and 3 of *Clinical Hematology* focus on erythrocytes and leukocytes, respectively. The content of the chapters in each of these parts progresses from normal structure and function to specific abnormalities in each grouping.

In Part 4, Additional Groups of Clonal Disorders, is in focus. Each of the two chapters investigates multiple disorders that share a common clonal origin.

Part 5, Principles and Disorders of Hemostasis and Thrombosis, presents a distinct specialty in hematology: blood coagulation. An abundance of new knowledge about platelets and coagulation factors continues to emerge.

The final part, Part 6, focuses on hematological analysis. This section includes diversified types of analysis including body fluid analysis, manual procedures, and instrumentation. This part is conveniently located at the end of the book for easy reference when reading other parts of the book.

Handy appendices include answers to review questions, medical terminology basics, SI units, a list of English-Spanish medical phrases for the phlebotomist, the newest evacuated tube pictorial directory, and a sample Material Safety Data Sheet (MSDS). A glossary at the end of the book defines all the key words bolded throughout the text.

CHAPTER STRUCTURE AND FEATURES

Each chapter of *Clinical Hematology* provides the following elements to enhance the usability of the text:

- **Learning objectives** provide a quick overview of the content to be covered.
- **Case studies** reinforce concepts with real-world applications.
- **Procedure boxes** provide step-by-step information for key processes.
- **Key terms** that emphasize important concepts are italicized and defined in the end-of-book glossary.
- **Review questions** reinforce the student's understanding of key concepts and aid in test preparation.
- **Chapter highlights** enable a quick review of material learned in each chapter.

ADDITIONAL RESOURCES

Clinical Hematology includes additional resources for both instructors and students that are available on the book's companion Web site at <http://thePoint.lww.com/Turgeon5e>.

Instructor Resources

Approved adopting instructors will be given access to the following additional resources:

- Two test banks—one contains more than 800 unique questions; the other contains all the review questions from the book
- PowerPoint slides for each chapter
- An image bank of all the figures and tables in the book

Student Resources

Students who have purchased *Clinical Hematology*, 5th edition have access to the following additional resources:

- A quiz bank of 270 questions
- A lab manual of additional procedures

In addition, purchasers of the text can access the searchable Full Text On-line by going to the *Clinical Hematology* Web site at <http://thePoint.lww.com/Turgeon5e>.

ACKNOWLEDGMENTS

My objective in writing *Clinical Hematology*, 5th edition, continues to be to share basic scientific concepts, procedural theory, and clinical applications with fellow teachers and students. Because the knowledge base and technology in hematology continues to expand, writing and revising a book that addresses the need of teachers and students at multiple levels in the clinical sciences continue to be a challenge. In addition, this book continues to provide me with the opportunity to learn and share my working and teaching experience, and insight as an educator, with others.

Special thanks to John Goucher for initiating the project and to Meredith Brittain for her organizational efforts in the process of turning the manuscript into a four-color book. An additional thank you is extended to Christine Selvan and her team at SPi for their excellent performance in the preparation of the manuscript for publication.

Comments from instructors and students are welcome at m.turgeon@neu.edu.

Mary L. Turgeon
Boston, Massachusetts
St. Petersburg, Florida

CONTENTS

Preface iv

PART ONE:

The Principles of Hematology

1

1	Safety and Quality in the Hematology Laboratory	1
	An Overview of the Hematology Laboratory	1
	The Study of Hematology	1
	Functions of the Hematology Laboratory	1
	Safety in the Hematology Laboratory	2
	The Safety Officer	2
	Occupational Safety and Health Administration Acts and Standards	2
	Avoiding Transmission of Infectious Diseases	3
	Immune Status: Screening and Vaccination	5
	Safe Work Practices and Protective Techniques for Infection Control	6
	Safety Manual, Policies, and Practices	6
	Standard Precautions	6
	Handwashing	6
	Personal Protective Equipment	7
	Decontamination of Work Surfaces, Equipment, and Spills	8
	General Infection Control Safety Practices	9
	OSHA Medical Waste Standards	11
	Quality Assessment in the Hematology Laboratory	12
	Regulations and Organizations Impacting Quality	12
	Components of Quality Assessment	12
	Nonanalytical Factors in Quality Assessment	12
	Quality Control in the Hematology Laboratory	16
	Terms Used in Clinical Quality Control	16
	Functions of a Quality Control Program	17
	Using Statistical Analysis of Results in Quality Assessment	18
	Other Statistical Applications in the Hematology Laboratory	20
	■ CHAPTER HIGHLIGHTS	20
	■ REVIEW QUESTIONS	21
	■ BIBLIOGRAPHY	23
2	Principles of Blood Collection	25
	Quality in Phlebotomy	25
	Quality Assessment	25
	Patient Care Partnership	25
	The Phlebotomist as Laboratory Ambassador	26
	Patients with Special Considerations	26
	Pediatric Patients	26
	Adolescent Patients	26
	Geriatric Patients	26
	Blood Collection Supplies and Equipment	26
	Anticoagulants	26
	Adverse Effects of Additives	27
	Safe Blood Collection	27
	Evacuated Blood Collection Tubes	29
	Anticoagulants and Additives in Evacuated Blood Tubes	31
	Capillary Blood	31
	Specimen Handling Requirements	32
	■ CHAPTER HIGHLIGHTS	45

- REVIEW QUESTIONS 47
- REFERENCE 48
- BIBLIOGRAPHY 48

3 Molecular Genetics and Cellular Morphology50

Cellular Ultrastructure and Organization	50
Cellular Membranes	50
Cell Volume Homeostasis	52
Reactive and Neoplastic Growth Processes	53
Cytoplasmic Organelles and Metabolites	53
Cellular Inclusions and Metabolites	54
Nuclear Characteristics	54
Chromosomes	56
Activities of the Nucleus	58
The Foundations of Genetic Interactions	60
Genetic Alterations	61
Molecular Techniques in Hematology	63
Minimal Residual Disease	63
Hematopathology	67
Gene Rearrangement Studies	69

- CHAPTER HIGHLIGHTS 69
- REVIEW QUESTIONS 70
- BIBLIOGRAPHY 72

4 Hematopoiesis 73

Hematopoiesis Defined	73
Origin of Blood Cells	73
Types of Human Stem Cells	73
Early Development of Blood Cells	73
Bone Marrow Sites and Function	75
Cellular Elements of Bone Marrow	76
Progenitor Blood Cells	76
Erythropoiesis	79
Granulopoiesis	79
Lymphopoiesis	79
Megakaryopoiesis	79
Other Cells Found in Bone Marrow	79
Interleukins	79
Hematopoietic Growth Factors	82
Examination of Maturing Blood Cells	83
General Cellular Characteristics	83
Nuclear Characteristics	83
Cytoplasmic Characteristics	85
Mature Blood Cells in Peripheral Blood	86
■ CHAPTER HIGHLIGHTS	86
■ REVIEW QUESTIONS	87
■ BIBLIOGRAPHY	87

PART TWO:

Erythrocytes

89

5 Erythrocyte Maturation, Physiology, and Lifecycle 89

Erythropoiesis	90
Erythropoietin	90
General Characteristics of Maturation and Development	91
Developmental Stages	92
Reticulocytes	94

Disorders Related to Erythrocyte Maturation and Production	97
<i>Disorders of Erythropoietin</i>	97
<i>Red Cell Increases</i>	98
<i>Defective Nuclear Maturation</i>	98
Characteristics and Biosynthesis of Hemoglobin	98
<i>Genetic Inheritance of Hemoglobin</i>	98
<i>Chemical Composition and Configuration of Hemoglobin</i>	98
<i>The Role of 2,3-Diphosphoglycerate</i>	99
<i>Oxygen Dissociation and Alterations</i>	99
<i>Carbon Dioxide Transport</i>	100
<i>Biosynthesis of Hemoglobin</i>	101
Disorders Related to Hemoglobin Biosynthesis	104
<i>Disorders of Heme (Porphyrin) Synthesis</i>	104
<i>Disorders of Iron Metabolism</i>	105
<i>Disorders of Globulin Synthesis</i>	108
<i>Ontogeny of Hemoglobin</i>	108
<i>Variant Forms of Normal Hemoglobin</i>	109
<i>Abnormal Hemoglobin Molecules</i>	110
<i>Analysis of Hemoglobin</i>	110
Membrane Characteristics and Metabolic Activities of Erythrocytes	111
<i>Membrane Characteristics</i>	112
<i>Cytoplasmic Characteristics</i>	113
<i>Metabolic Activities</i>	113
<i>Catabolism of Erythrocytes</i>	114
Measurement of Erythrocytes	116
<i>Mean Corpuscular Volume</i>	116
<i>Mean Corpuscular Hemoglobin</i>	117
<i>Mean Corpuscular Hemoglobin Concentration</i>	117
■ CHAPTER HIGHLIGHTS	118
■ CASE STUDIES	119
■ REVIEW QUESTIONS	121
■ BIBLIOGRAPHY	124
6 Erythrocyte Morphology and Inclusions	126
Erythrocytes: Normal and Abnormal	126
Types of Variations in Erythrocyte Size	126
Kinds of Variations in Erythrocyte Shape	127
Alterations in Erythrocyte Color	134
Varieties of Erythrocyte Inclusions	135
Alterations in Erythrocyte Distribution	137
Parasitic Inclusions in Erythrocytes	137
<i>Malaria</i>	137
<i>Other Parasitic Inclusions</i>	141
■ CHAPTER HIGHLIGHTS	142
■ CASE STUDY	142
■ REVIEW QUESTIONS	143
■ BIBLIOGRAPHY	144
7 Classification and Laboratory Assessment of Anemias	145
Causes of Anemia	145
Clinical Signs and Symptoms of Anemia	145
Classification of Anemias	145
Laboratory Assessment of Anemias	146
<i>Quantitative Measurements of Anemia</i>	147
<i>Semiquantitative Grading of Erythrocyte Morphology</i>	147
<i>Supplementary Assessment of Anemias</i>	148
■ CHAPTER HIGHLIGHTS	148
■ REVIEW QUESTIONS	148
■ BIBLIOGRAPHY	149
8 Acute and Chronic Blood Loss Anemias	150
Acute Blood Loss Anemia	150
<i>Etiology</i>	150
<i>Physiology</i>	150
<i>Laboratory Findings</i>	150
Chronic Blood Loss Anemia	150
<i>Etiology</i>	150
■ CHAPTER HIGHLIGHTS	151
■ CASE STUDIES	151
■ REVIEW QUESTIONS	153
■ BIBLIOGRAPHY	153
9 Aplastic and Related Anemias	154
Aplastic Anemia	154
<i>Etiology</i>	154
<i>Pathophysiology</i>	155
<i>Clinical Features</i>	158
<i>Laboratory Findings</i>	158
<i>Treatment</i>	158
Congenital Red Blood Cell–Related Disorders	159
<i>Telomeres</i>	159
<i>Laboratory Findings in Bone Marrow Failure Syndromes</i>	160
<i>Pure Red Cell Aplasia</i>	160
<i>Diamond-Blackfan Anemia</i>	160
<i>Fanconi Anemia</i>	161
<i>Transient Erythroblastopenia of Childhood</i>	162
<i>Congenital Dyserythropoietic Anemia</i>	163
■ CHAPTER HIGHLIGHTS	163
■ CASE STUDIES	163
■ REVIEW QUESTIONS	165
■ BIBLIOGRAPHY	165
10 Iron Deficiency Anemia and Anemia of Chronic Inflammation	166
Scope of the Problem	166
Iron Deficiency Anemia	166
<i>Early Diagnosis</i>	166
<i>Etiology</i>	166
<i>Epidemiology</i>	167
<i>Physiology</i>	168
<i>Pathophysiology</i>	169
<i>Clinical Signs and Symptoms</i>	170
<i>Laboratory Characteristics</i>	170
Anemia of Inflammation or Anemia of chronic Disorders	173
<i>Etiology</i>	173
<i>Pathophysiology</i>	173
<i>Laboratory Characteristics</i>	174
<i>Treatment</i>	175
■ CHAPTER HIGHLIGHTS	175
■ CASE STUDIES	176
■ REVIEW QUESTIONS	179
■ BIBLIOGRAPHY	180
11 Megaloblastic Anemias	181
Megaloblastic Anemias	181
<i>Etiology</i>	181
<i>Epidemiology</i>	182
<i>Physiology</i>	182
<i>Vitamin B₁₂ (Cobalamin) Transport</i>	182
<i>Vitamin B₁₂ (Cobalamin) and Folic Acid Deficiencies</i>	183
<i>Pathophysiology</i>	184
<i>Gastric Pathological Findings</i>	184
<i>Clinical Signs and Symptoms</i>	186
<i>Laboratory Findings</i>	186
<i>Treatment and Monitoring Therapy</i>	188
■ CHAPTER HIGHLIGHTS	188
■ CASE STUDY	190
■ REVIEW QUESTIONS	191
■ BIBLIOGRAPHY	191

12 Hemolytic Anemias 192

- Hemolytic Anemias 192
 - Inherited Hemolytic Anemia* 192
 - Acquired Hemolytic Anemia* 197
 - Pathophysiology* 200
 - Diagnostic Tests* 201
- Paroxysmal Nocturnal Hemoglobinuria 201
 - Etiology* 201
 - Epidemiology* 202
 - Pathophysiology* 202
 - Clinical Signs and Symptoms* 202
 - Laboratory Findings* 203
 - Treatment* 203
- Paroxysmal Cold Hemoglobinuria 203
- CHAPTER HIGHLIGHTS 203
- CASE STUDIES 204
- REVIEW QUESTIONS 207
- BIBLIOGRAPHY 208

13 Hemoglobinopathies and Thalassemias 210

- Hemoglobin Defects 210
 - Demographics* 210
 - Etiology* 210
- Sickle Cell Disease 211
 - Etiology* 212
 - Epidemiology* 212
 - Pathophysiology* 212
 - Clinical Signs and Symptoms* 213
 - General Signs and Symptoms* 214
 - Laboratory Testing* 214
 - Special Laboratory Testing* 215
 - Management of Sickle Cell Disease* 216
- Sickle Cell Syndromes: Pathogenesis and New Approaches 218
 - Sickle β -Thalassemia* 218
 - Sickle-C Disease* 219
 - Sickle Cell Trait* 219
- Thalassemia 220
 - Demographics* 220
 - Etiology* 220
 - Pathophysiology* 220
 - β -Thalassemia* 220
 - α -Thalassemia* 223
- Other Hemoglobinopathies 224
 - Hemoglobin C Disease* 224
 - Hemoglobin SC Disease* 224
 - Hemoglobin D Disease* 224
 - Hemoglobin E Disease* 224
 - Hemoglobin H Disease* 225
 - Methemoglobinemia* 225
 - Unstable Hemoglobins* 225
- Hereditary Persistence of Fetal Hemoglobin 225
- CHAPTER HIGHLIGHTS 226
- CASE STUDIES 227
- REVIEW QUESTIONS 232
- BIBLIOGRAPHY 233

PART THREE:**Leukocytes 235****14 Leukocytes: The Granulocytic and Monocytic Series 235**

- Introduction 235
- The Granulocytic Series 235
 - Production of Neutrophils, Eosinophils, and Basophils* 235
 - Sites of Development and Maturation* 236

- Development and Proliferation of Neutrophils, Eosinophils, and Basophils* 236
- Distribution of Neutrophils, Eosinophils, and Basophils* 236
- Normal Maturation Characteristics of Neutrophils, Eosinophils, and Basophils* 237
- Mature Forms* 239
- Granulation in Mature Forms* 239

- The Monocytic-Macrophage Series 240
 - Production and Development of Monocytes and Macrophages* 240
 - Morphological Characteristics* 241

- Reference Ranges of Granulocytes and Monocytes 241

- Functional Properties of Granulocytes and Monocytes 242

- General Characteristics* 243
- The Role of Macrophages* 243
- Acute Inflammatory Response* 243
- Sepsis* 245
- Steps in Phagocytosis* 245
- Specialized Functions of Granulocytes* 247

- Assessment Methods 248

- Total Leukocyte Count* 248
- Differential Blood Smear Evaluation* 248
- Absolute Cell Counts* 248
- Erythrocyte Sedimentation Rate* 248
- Assessment of Eosinophils and Basophils* 249
- Leukocyte Alkaline Phosphatase Test* 249
- Neutrophilic Function* 249
- Neutrophilic Hypersegmentation Index* 249

- CHAPTER HIGHLIGHTS 249
- CASE STUDY 250
- REVIEW QUESTIONS 251
- BIBLIOGRAPHY 253

15 Nonmalignant Disorders of Granulocytes and Monocytes 254

- Quantitative Disorders 254
 - Leukocytosis* 254
 - Leukocytopenia* 255
- Morphological Abnormalities of Mature Granulocytes 256
 - Toxic Granulation* 256
 - Döhle Bodies* 256
 - Hypersegmentation* 256
 - Pelger-Huët Anomaly* 256
 - May-Hegglin Anomaly* 257
 - Chédiak-Higashi Syndrome* 257
 - Alder-Reilly Inclusions* 258
 - Ehrlichia* 258
 - Abnormalities of Mature Granulocytes in Body Fluids* 258

- Qualitative Disorders 258
 - Defective Locomotion and Chemotaxis* 258
 - Defects in Microbicidal Activity* 259
 - Other Functional Anomalies of Neutrophils* 259

- Monocyte-Macrophage Disorders 259

- Gaucher Disease* 259
- Niemann-Pick Disease* 260

- CHAPTER HIGHLIGHTS 260
- CASE STUDIES 260
- REVIEW QUESTIONS 264
- BIBLIOGRAPHY 265

16 Leukocytes: Lymphocytes and Plasma Cells . . . 266

- Anatomical Origin and Development of Lymphocytes 266
 - Sites of Lymphocytic Development* 266
 - Lymphocyte Physiology* 267
 - Normal Reference Values* 267
 - Determining Absolute Lymphocyte Values* 268
- Morphological Characteristics of Normal Lymphocytes 268
 - Maturation Stages* 269
 - Specific Lymphocyte Morphological Variations* 272

Characteristics of Lymphocytes	273	General Characteristics of Acute Myeloid Leukemias	309
Major Lymphocyte Categories and Functions	273	Genetic Differences	309
Monoclonal Antibodies	274	Micro-RNAs	310
Major Lymphocyte Membrane Characteristics and Development	274	Acute Myeloid Leukemia	310
Functional Testing of Lymphocytes	277	FAB M0	311
Plasma Cell Development and Maturation	277	Acute Myeloid Leukemia (FAB M1)	311
Plasma Cell Development	277	Acute Myeloid Leukemia (FAB M2)	312
Maturation Morphology	277	Acute Promyelocytic Leukemia (FAB M3)	312
Plasmacytoid Lymphocytes	277	Acute Myelomonocytic Leukemia (FAB M4)	313
Plasma Cell Disorders	278	Acute Monocytic Leukemia (FAB M5)	314
■ CHAPTER HIGHLIGHTS	278	Erythroleukemia (FAB M6)	315
■ REVIEW QUESTIONS	279	Selected Examples of Unusual Forms	316
■ BIBLIOGRAPHY	280	Acute megakaryoblastic leukemia FAB M7	316
17 Leukocytes: Nonmalignant Lymphocytic Disorders	281	Epidemiology of Acute Lymphoblastic Leukemia	316
Characteristics of Lymphocytes	281	Prognosis of Acute Lymphoblastic Leukemia	317
Lymphocytosis	281	Classifications of Acute Lymphoblastic Leukemia	317
Disorders Associated with Lymphocytosis	282	Characteristics of Acute Lymphoblastic Leukemia	317
Infectious Mononucleosis	282	Clinical Signs and Symptoms	317
Cytomegalovirus Infection	286	Laboratory Data	317
Toxoplasmosis	287	Special Identification Techniques	318
Infectious Lymphocytosis	288	Treatment	319
Bordetella pertussis (Haemophilus pertussis) Infection	289	Mixed Lineage Leukemia	319
Lymphocytopenia	289	Cytogenetic Analysis	319
Immune Disorders Associated with Lymphocytopenia	289	Cytogenetic Analysis in Acute Myeloid Leukemia	319
DiGeorge Syndrome	289	Cytogenetics in Acute Lymphoblastic Leukemia	320
Acquired Immunodeficiency Syndrome (HIV/AIDS)	289	Principles of Special Cytochemical Stains	320
Systemic Lupus Erythematosus	293	Sudan Black B Stain	321
■ CHAPTER HIGHLIGHTS	294	Myeloperoxidase Stain	326
■ CASE STUDIES	294	Periodic Acid-Schiff Stain	322
■ REVIEW QUESTIONS	297	Esterase Stains	323
■ BIBLIOGRAPHY	297	Phosphatase Stains	324
18 Characteristics of Leukemias, Lymphomas, and Myelomas	298	Monoclonal Antibodies	325
Comparison of Leukemias, Lymphomas, and Myelomas	298	Immunophenotyping	325
Forms of Leukemia	298	Lymphoid	325
Classifications of Leukemias	299	Other Surface Membrane Markers	326
French-American-British Classification	299	Life-Threatening Emergencies	326
World Health Organization Classification	299	Infection	326
Prognosis and Treatment	300	Bleeding	326
Factors Related to the Occurrence of Leukemia	300	Leukemic Infiltration of Organs	326
Genetic and Immunological Factors	300	Metabolic Abnormalities	326
Occupational Exposure	302	Hyperleukocytosis	327
Environmental Exposure	302	Treatment Options	327
Chemical and Drug Exposure	302	Relapse	328
Genetic Abnormalities and Associations	302	Stem Cell Transplant	328
Viral Agents	303	Future Trends Vaccines	328
Secondary Causes of Leukemias	303	■ CHAPTER HIGHLIGHTS	328
Demographic Distribution of Leukemia and Lymphomas	304	■ CASE STUDIES	329
Ethnic Origin and Race	304	■ REVIEW QUESTIONS	333
Gender	305	■ BIBLIOGRAPHY	335
■ CHAPTER HIGHLIGHTS	305	20 Lymphoid and Plasma Cell Neoplasms	337
■ REVIEW QUESTIONS	306	Mature B-Cell Neoplasms	
■ BIBLIOGRAPHY	306	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	337
19 Acute Leukemias	307	Epidemiology	337
Introduction	307	Etiology	337
Epidemiology of Acute Leukemias	307	Cytogenetics	338
Prognosis of Acute Leukemias	308	Molecular Genetics	339
French-American-British and World Health Organization Categories	308	Staging and Prognosis	339
French-American-British (FAB) Classification	308	Clinical Signs and Symptoms	340
World Health Organization (WHO) Organization Classification	308	Laboratory Data	341
		Treatment Options	341
		Minimal Residual Disease	342
		Hairy Cell Leukemia	342
		Hairy Cell Leukemia Variant	343
		Prolymphocytic Leukemia	344

Multiple Myeloma (Plasma Cell Myeloma)	344
Epidemiology	344
Etiology	344
Clinical Signs and Symptoms	344
Laboratory Data	344
Treatment	345
Waldenström Primary Macroglobulinemia (Lymphoplasmacytic lymphoma)	346
Epidemiology	346
Etiology	346
Clinical Signs and Symptoms	346
Laboratory Data	346
Treatment	347
Lymphomas	347
Relationship Between Lymphomas and Leukemias	347
Characteristics	347
Categories	347
Pathophysiology	349
Precursors of Hodgkin Disease and B-Cell Lymphomas	350
Hodgkin Disease	350
Non-Hodgkin Lymphoma	351
Characteristics of Other Forms	352
Sézary Syndrome	353
Mature T-Cell and NK-Cell Neoplasms	353
■ CHAPTER HIGHLIGHTS	353
■ CASE STUDIES	354
■ REVIEW QUESTIONS	358
■ BIBLIOGRAPHY	358

PART FOUR:

Myeloproliferative Neoplasms 361

21 Myeloproliferative Neoplasms 361

General Characteristics of Myeloproliferative Neoplasms	362
Relationship of the Myeloproliferative Neoplasms	362
Common Disorders of Hemostasis and Coagulation	362
Prognosis and Treatment	363
Chronic Myelogenous Leukemia	363
Epidemiology	363
Pathophysiology	363
Cytogenetics	364
Genetic Alterations	364
Laboratory Data	365
Cytogenetic Studies	367
Prognosis and Treatment	367
Minimal Residual Disease	368
Leukemia-Specific Targets	369
Allogeneic Bone Marrow Transplantation	370
Polycythemia Vera, Essential Thrombocythemia (Essential Thrombocythemia), and Primary Myelofibrosis	370
Polycythemia Vera	370
Epidemiology	370
Etiology	370
Pathophysiology	370
Karyotype	371
Clinical Signs and Symptoms	371
Laboratory Data	371
Abnormalities of Hemostasis and Coagulation	372
Other Laboratory Assays	372
Treatment	373
Prognosis and Complications	374
Primary Myelofibrosis	374
Epidemiology	374
Pathophysiology	374
Karyotype	375

Clinical Signs and Symptoms	375
Cellular Alterations	375
Prognosis	376
Treatment	376
Essential Thrombocythemia/Essential Thrombocythemia	376
Diagnostic Characteristics	376
Epidemiology	377
Pathophysiology	377
Karyotype	377
Clinical Signs and Symptoms	377
Laboratory Findings	377
Relationship of Thrombocythemia and PV	377
Treatment	378
■ CHAPTER HIGHLIGHTS	378
■ CASE STUDIES	379
■ REVIEW QUESTIONS	382
■ BIBLIOGRAPHY	384

22 Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms 386

Classification	386
Myelodysplastic Syndromes	386
Myelodysplastic/myeloproliferative neoplasms	386
Pathophysiology	387
Myelodysplastic Syndrome	387
Etiology	388
Epidemiology	389
Chromosomal Abnormalities	389
Clinical Signs and Symptoms	390
Laboratory Manifestations	390
Features of Selected Types of Myelodysplastic Syndromes	391
Myelodysplastic/Myeloproliferative Neoplasms	392
Chronic myelomonocytic leukemia	392
Other Classifications	393
Treatment Strategies	393
Relationship of Karyotype to Prognosis	394
■ CHAPTER HIGHLIGHTS	395
■ CASE STUDIES	396
■ REVIEW QUESTIONS	397
■ BIBLIOGRAPHY	398

PART FIVE:

Principles and Disorders of Hemostasis and Thrombosis 399

23 Principles of Hemostasis and Thrombosis 399

Overview of Hemostasis and Thrombosis	400
Blood Vasculture: Structure and function	400
Arteries and Veins	400
Arterioles and Venules	400
Capillaries	400
Vasculture Physiology	401
The Role of Vasoconstriction in Hemostasis	401
The Role of the Endothelium	401
Maintenance of Vascular Integrity	402
The Megakaryocytic Cell Series	403
General Characteristics of Megakaryocytic Development	403
Cellular Ultrastructure of a Mature Platelet	405
Platelet Kinetics, Life Span, and Normal Values	406
Platelet Function in Hemostasis	406
Overall Functions of Platelets	406
Platelet Adhesion	406
Platelet Aggregation	407
Platelet Plug Consolidation and Stabilization	408
Laboratory Assessment of Platelets	408

Blood Coagulation Factors	410
<i>Basic Concepts of Blood Coagulation</i>	410
<i>Common Characteristics of Coagulation Factors</i>	410
<i>Characteristics of Individual Factors</i>	410
<i>The Mechanism of Coagulation</i>	413
<i>Coagulation Pathways</i>	413
<i>Thrombin-Mediated Reactions</i>	414
<i>Fibrinolysis</i>	414
<i>Other Systems and Inhibitors</i>	415
<i>Laboratory Assessment of Blood Coagulation Factors</i>	416
<i>International Normalized Ratio</i>	416
<i>Specialized Assays for Coagulation Factors</i>	417
<i>Anticoagulants</i>	417
<i>New Thromboplastins</i>	418
<i>Assays for Fibrin Formation</i>	419
Normal Protective Mechanisms Against Thrombosis	420
<i>Normal Blood Flow</i>	420
<i>Removal of Activated Clotting Factors and Particulate Material</i>	420
<i>The Natural Anticoagulant Systems</i>	420
<i>Cellular Regulators</i>	424
Modern View of Hemostasis	424
■ CHAPTER HIGHLIGHTS	424
■ REVIEW QUESTIONS	426
■ BIBLIOGRAPHY	429
24 Disorders of Hemostasis and Thrombosis	431
Vascular Disorders	431
Abnormal Platelet Morphology	432
Quantitative Platelet Disorders	432
<i>Thrombocytopenia</i>	432
<i>Thrombocytosis</i>	436
Qualitative Characteristics of Platelets:	
Thrombocytopathy	436
<i>Types of Platelet Dysfunctions</i>	437
Bleeding Disorders Related to Blood Clotting	439
<i>Defective Production</i>	440
<i>Disorders of Destruction and Consumption</i>	445
<i>Disorders Related to Elevated Fibrin Split Products</i>	449
The Hypercoagulable State	450
<i>Primary States of Hypercoagulability</i>	450
<i>Secondary States of Hypercoagulability</i>	450
<i>Pregnancy-Associated Thrombosis</i>	450
<i>General Features</i>	451
<i>Impaired Fibrinolysis</i>	454
<i>Antithrombin III Deficiency</i>	456
<i>Laboratory Assessment of Hypercoagulable States</i>	457
■ CHAPTER HIGHLIGHTS	458
■ CASE STUDIES	460
■ REVIEW QUESTIONS	462
■ BIBLIOGRAPHY	463

PART SIX:**Fundamentals of Hematological Analysis 465****25 Body Fluid Analysis 465**

Introduction	466
Cerebrospinal Fluid	466
<i>Anatomy and Physiology</i>	466
<i>Production of Cerebrospinal Fluid</i>	466
<i>Specimen Collection: Lumbar Puncture</i>	466
<i>Laboratory Analysis</i>	467
Pleural, Peritoneal, and Pericardial Fluids	473
<i>Effusions: Transudates and Exudates</i>	473
<i>Pleural Fluid</i>	473

<i>Peritoneal Fluid</i>	478
<i>Pericardial Fluid</i>	482
<i>Seminal Fluid</i>	484
<i>Synovial Fluid</i>	486
<i>Anatomy and Physiology of Joints</i>	486
<i>Purpose of Arthrocentesis</i>	486
<i>Aspiration</i>	487
<i>Laboratory Assays</i>	487
<i>Body Fluid Slide Preparation</i>	490
<i>Staining of Body Fluid Sediment</i>	490
<i>Amniotic Fluid</i>	490
■ CHAPTER HIGHLIGHTS	490
■ REVIEW QUESTIONS	493
■ BIBLIOGRAPHY	496

26 Manual Procedures in Hematology 498

Procedural Format	498
Coagulation Procedures	516
<i>Specimen Quality</i>	516
<i>Special Collection Techniques</i>	516
<i>Anticoagulants</i>	517
<i>Specimen Handling</i>	517
<i>Specimen Preparation</i>	517
<i>General Sources of Error</i>	517
<i>Quality Control</i>	518
■ REVIEW QUESTIONS	522

27 Instrumentation in Hematology 526

Instrumental Principles	527
<i>The Electrical Impedance Principle</i>	527
<i>The Optical Detection Principle</i>	527
<i>Characteristics of Light Scatter</i>	527
<i>Radio Frequency</i>	528
<i>Fundamentals of Laser Technology</i>	528
<i>Principles of Flow Cytometry</i>	529
<i>The Basis of Cellular Identification</i>	529
Whole Blood Cell Analysis	531
<i>Types of Automated Cell Counting Instruments</i>	532
<i>General Histogram Characteristics</i>	543
Analysis of Instrumental Data Output	543
<i>The Erythrocyte Histogram</i>	543
<i>Quantitative Descriptors of Erythrocytes</i>	543
<i>The Leukocyte Histogram</i>	544
<i>Platelet Histograms</i>	545
<i>Derived Platelet Parameters</i>	546
Laser Technology	547
<i>Red Blood Cells/Platelets</i>	547
<i>Peroxidase</i>	548
<i>Basophil/Lobularity (Nuclear) Channel</i>	549
<i>Lymphocyte Subtyping</i>	549
Applications of Flow Cytometry	549
<i>General Properties of Flow Cytometry</i>	550
<i>Hematological Applications</i>	550
<i>Clinical Applications of Flow Cytometry</i>	550
<i>Other Cellular Applications</i>	551
Digital Microscopy	554
<i>Artificial Neural Networks</i>	554
<i>Digital Cell Morphology</i>	554
Instruments in Coagulation Studies	555
<i>Electromechanical Methods</i>	555
<i>Photo-Optical Methods</i>	555
<i>Viscosity-based Detection System</i>	558
<i>Platelet Agglutination</i>	559
<i>Platelet Aggregation</i>	559
<i>New Automation</i>	559
Summary	559
<i>Instrumental Principles</i>	559
<i>Analysis of Electrical Impedance Instrumental Data Output</i>	559

<i>Laser Technology</i>	560
<i>Applications of Flow Cytometry</i>	560
<i>Instruments in Coagulation Studies</i>	560
■ CASE STUDIES	560
■ REVIEW QUESTIONS	569
■ BIBLIOGRAPHY	571

APPENDICES

A Answers to Review Questions	573
B The Basics of Medical Terminology	578
C SI Units	580

D English-Spanish Medical Phrases for the Phlebotomist	581
E MSDS Sheet	582
F Tube Guide	588
G Frequently Used Abbreviations	590

Glossary 591

Index 602

The Principles of Hematology

CHAPTER

1

Safety and Quality in the Hematology Laboratory

OBJECTIVES

An overview of the hematology laboratory

- Explain the role of the hematology laboratory staff in providing quality patient care.
- List five basic functions of the hematology laboratory.

Safety in the hematology laboratory

- Explain the basic techniques in the prevention of disease transmission.
- Compare the features of general safety regulations governing the clinical laboratory, including components of the Occupational Safety and Health Administration (OSHA)-mandated plans for chemical hygiene and for occupational exposure to bloodborne pathogens, and the importance of the laboratory safety manual.
- List and describe the basic aspects of infection control policies and practices, including how and when to use personal protective equipment or devices (e.g., gowns, gloves, goggles), and the reasons for using standard precautions.

- Explain the purpose and correct procedure of handwashing.
- Describe the contents of the laboratory procedures manual.

Quality Assessment and quality control in the hematology laboratory

- Summarize the essential nonanalytical factors in quality assessment.
- Briefly describe computer-based control systems.
- Define terms used in quality control and basic statistical terms.
- Describe the basic terms and state the formulas for the standard deviation, coefficient of variation, and z score.
- Describe the use of a Levey-Jennings quality control chart.
- Compare three types of changes that can be observed in a quality control chart.
- Explain the most frequent application of a histogram.

AN OVERVIEW OF THE HEMATOLOGY LABORATORY

Hematology, the discipline that studies the development and diseases of blood, is an essential medical science. In this field, the fundamental concepts of biology and chemistry are applied to the medical diagnosis and treatment of various disorders or diseases related to or manifested in the blood and bone marrow.

The Study of Hematology

Basic procedures performed in the hematology laboratory, such as the complete blood cell count (CBC), which includes the measurement and examination of red blood cells (erythrocytes), white blood cells (leukocytes), and platelets (thrombocytes), and the erythrocyte sedimentation rate (ESR), frequently guide the primary care provider in establishing a

patient's differential diagnosis. Molecular diagnostics, flow cell cytometry, and digital imaging are modern techniques that have revolutionized the laboratory diagnosis and monitoring of many blood disorders, for example, acute leukemias and inherited blood disorders. The field of hematology encompasses the study of blood coagulation—hemostasis and thrombosis.

Functions of the Hematology Laboratory

Medical laboratory scientists, medical laboratory technicians, laboratory assistants, and phlebotomists employed in the hematology laboratory play a major role in patient care.

The assays and examinations that are performed in the laboratory can do the following:

- Establish a diagnosis or rule out a diagnosis
- Confirm a physician's clinical impression of a possible hematological disorder

- Detect an unsuspected disorder
- Monitor the effects of therapy
- Detect minimal residual disease following therapy

Although the CBC is the most frequently requested procedure, a laboratory professional must be familiar with the theory and practice of a wide variety of automated and manual tests performed in the laboratory to provide quality patient care. Continuing education is a necessity to keep up with continually changing knowledge and instrumentation in the field.

SAFETY IN THE HEMATOLOGY LABORATORY

The practice of safety should be uppermost in the mind of all persons working in a clinical hematology laboratory. Accidents do not just happen; they are caused by carelessness, lack of attention to detail, or lack of proper communication. Most laboratory accidents are preventable by exercising good technique, staying alert, and using common sense.

Safety standards for patients and clinical laboratories are initiated, governed, and reviewed by governmental agencies and professional organizations (see Box 1.1). The Joint Commission (www.jointcommission.org) has established National Patient Safety Goals. One of the goals of particular interest to laboratory professionals addresses the issue of critical laboratory assay values, the high and low boundaries of the life-threatening values of laboratory test results (see “Quality Assessment in the Hematology Laboratory”). Urgent clinician notification of critical results is the responsibility of the laboratory.

The Safety Officer

A designated safety officer is a critical part of a laboratory safety program. This individual has many duties affecting staff including compliance with existing regulations affecting the laboratory and staff, for example, labeling of chemicals and providing supplies for the proper handling and disposal of biohazardous materials.

BOX 1.1

Safety Agencies and Organizations

- U.S. Department of Labor’s Occupational Safety and Health Administration (OSHA)
- Clinical and Laboratory Standards Institute (CLSI)
- CDC, part of the U.S. Department of Health and Human Services (DHHS), Public Health Service
- College of American Pathologists (CAP)
- The Joint Commission (The Joint Commission on Accreditation of Healthcare Organizations)

Occupational Safety and Health Administration Acts and Standards

To ensure safe and healthful working conditions for workers, the US federal government created a system of safeguards and regulations under the Occupational Safety and Health Act of 1970. In 1988, the Act expanded the Hazard Communication Standard to apply to hospital staff. The programs deal with many aspects of safety and health protection and places responsibility for compliance on management and employees.

The Occupational Safety and Health Administration (OSHA) standards include provisions for warning labels or other appropriate forms of warning to alert all workers to potential hazards, suitable protective equipment, exposure control procedures, and implementation of training and education programs. The primary purpose of OSHA standards is to ensure safe and healthful working conditions for every US worker.

OSHA and the Centers for Disease Control and Prevention (CDC) have published numerous safety standards and regulations that are applicable to clinical laboratories (e.g., 1988 OSHA Hazard Communication Standard). Ensuring safety in the clinical laboratory includes the following measures:

- A formal safety program
- Specifically mandated plans (e.g., chemical hygiene, bloodborne pathogens)
- Identification of various hazards (e.g., chemical, biological)

Chemical Hygiene Plan

In 1991, OSHA mandated that all clinical laboratories must implement a chemical hygiene plan (CHP) and an exposure control plan. As part of the CHP, a copy of the material safety data sheet (MSDS) must be readily accessible and available to all employees at all times. This document ensures that laboratory workers are fully aware of the hazards associated with chemicals in their workplaces. The MSDS describes hazards, safe handling, storage, and disposal of hazardous chemicals. The information is provided by chemical manufacturers and suppliers about each chemical and accompanies the shipment of each chemical.

On September 30, 2009, OSHA published the long-awaited Proposed Rule to modify the Hazard Communication Standard (HCS) to conform with the United Nations’ (UN’s) Globally Harmonized System (GHS) of Classification and Labeling of Chemicals. OSHA has made a preliminary determination that the proposed modifications will improve the quality and consistency of information provided to employers and employees regarding chemical hazards and associated protective measures.

The proposed modifications to the chemical hazard communication (HAZCOM) standard include:

- Revised criteria for classification of chemical hazards
- Revised labeling provisions that include requirements for use of standardized signal words, pictograms, hazard statements, and precautionary statements
- A specified format for safety data sheets (currently known as material safety data sheets)

- Related revisions to definitions of terms used in the standard and requirements for employee training on labels and safety data sheets

OSHA is also proposing to modify provisions of a number of other standards, including standards for flammable and combustible liquids, process safety management, and most substance-specific health standards, to ensure consistency with the modified HCS requirements. OSHA currently anticipates a 2-year phase-in period for new hazard communication training requirements and a 3-year phase-in period for overall implementation once the Final Rule is published.

“Right to Know” Laws

Legislation on chemical hazard precautions, such as state “right to know” laws, and OSHA document 29 CFR 1910 set the standards for chemical hazard communication (HAZCOM) and determine the types of documents that must be on file in a laboratory. For example, a yearly physical inventory of all hazardous chemicals must be performed, and MSDSs should be made available in each department for use. Each institution should also have at least one centralized area where all MSDSs are stored.

Occupational Exposure to Bloodborne Pathogens

The OSHA-mandated program, Occupational Exposure to Bloodborne Pathogens, became law in March 1992. This regulation requires that laboratories develop, implement, and comply with a plan that ensures the protective safety of laboratory staff to potential infectious bloodborne pathogens, hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The law further specifies the rules for managing and handling medical waste in a safe and effective manner.

The CDC also recommends safety precautions concerning the handling of all patient specimens, known as standard precautions. The CLSI has also issued guidelines for the laboratory worker in regard to protection from bloodborne diseases spread through contact with patient specimens. In addition, the CDC provides recommendations for treatment after occupational exposure to potentially infectious material.

Avoiding Transmission of Infectious Diseases

History of Infectious Disease Prevention

The recognition of HIV-1 generated new policies from the CDC and mandated regulations by the OSHA. Current safety guidelines for the control of infectious disease are based on the original CDC publication, “Recommendations for Prevention of HIV Transmission in Health-Care Settings” (*MMWR*, Suppl 2S, 1987). Clarifications of safety practices appear in the 1988 CDC clarifications of the original guidelines (*MMWR*, 37(24), 1988); in the Department of Labor, OSHA’s “Occupational Exposure to Bloodborne Pathogens”: Part 1910 to title 29 of the Code of Federal Regulations, 64175–64182, (Fed Reg, 56(235), 1991); and in the U.S. Department of Health and Human Services’ “Regulations

for Implementing the Clinical Laboratory Improvement Amendments of 1988: A Summary” (*MMWR*, 41(RR-2), 1992). Laboratory personnel must remain alert to further updates of these policies.

The purpose of the standards for bloodborne pathogens and occupational exposure is to provide a safe work environment. OSHA mandates that an employer does the following:

- Educate and train all healthcare workers in standard precautions and in preventing bloodborne infections
- Provide proper equipment and supplies, for example, gloves
- Monitor compliance with the protective biosafety policies

HIV has been isolated from blood and body fluids, for example, semen, vaginal secretions, saliva, tears, breast milk, cerebrospinal fluid (CSF), amniotic fluid, and urine, but only blood, semen, vaginal secretions, and breast milk have been implicated in transmission of HIV to date. Recently, sperm cells themselves have been discovered to be capable of transmitting HIV. Evidence for the role of saliva in the transmission of virus is unclear, but standard precautions do not apply to saliva uncontaminated with blood.

Preventing Occupational Transmission of HBV and HIV

Blood is the single most important source of HIV, HBV, and other bloodborne pathogens in the occupational setting.

Needlestick Prevention

The CDC estimates that more than 380,000 needlestick injuries occur in US hospitals each year; approximately 61% of these injuries are caused by hollow-bore devices. Blood is the most frequently implicated infected body fluid in HIV and HBV exposure in the workplace.

An occupational exposure is defined as a percutaneous injury, for example, needlestick or cut with a sharp object, or contact by mucous membranes or nonintact skin (especially when the skin is chapped, abraded, or affected with dermatitis), or the contact is prolonged or involves an extensive area with blood, tissues, blood-stained body fluids, body fluids to which standard precautions apply, or concentrated virus.

Among healthcare personnel with documented occupationally acquired HIV infection, prior percutaneous exposure is the most prevalent route of infection. Certain percutaneous injuries carry a higher risk of infection. Risk of infection is greater with:

- A deep injury
- Late-stage HIV disease in the source patient
- Visible blood on the device that caused the injury
- Injury with a needle that had been placed in a source patient’s artery or vein

There are a small number of instances when HIV has been acquired through contact with nonintact skin or mucous membranes (i.e., splashes of infected blood in the eye or

aerosols). The risk of infection not only varies with the type of exposure but also may be influenced by:

- Amount of infected blood in the exposure
- Length of contact with infectious material
- Amount of virus in the patient's blood or body fluid or tissue at the time of exposure

On November 6, 2000, the Needlestick Safety and Prevention Act became law. The provisions of the new law include:

- Requires healthcare employers to provide safety-engineered sharp devices and needleless system to employees to reduce the risk of occupational exposure to HIV, hepatitis C, and other bloodborne disease.
- Expands the definition of engineering controls to include devices with engineered sharps injury protection.
- Requires that exposure control plans document consideration and implementation of safer medical devices designed to eliminate or minimize occupational exposure. These plans must be reviewed and updated at least annually.
- Requires each healthcare facility to maintain a sharps injury log with detailed information regarding percutaneous injuries.
- Requires employers to solicit input from healthcare workers when identifying and selecting sharps and document process.

The good news is that most occupational exposures do not result in infection. The average risk for HIV transmission after exposure to infected blood is low—about 3 per 1,000 injuries.

Sharps Prevention

The most widespread control measure required by OSHA and CLSI is the use of puncture-resistant sharps containers. (Fig. 1.1). The primary purpose of using these containers is to eliminate the need for anyone to transport needles and other sharps while looking for a place to discard them. Sharps containers are to be located in the patient areas as well as conveniently placed in the laboratory.



FIGURE 1.1 Puncture-resistant sharps containers. (Courtesy of Becton Dickinson, Franklin Lakes, New Jersey.)

Phlebotomists should carry these red, puncture-resistant containers in their collection trays. Needle containers should not project from the top of the container. Use of the special sharps container permits quick disposal of a needle without recapping as well as of other sharp devices that may be contaminated with blood. This supports the recommendation against recapping, bending, breaking, or otherwise manipulating any sharp needle or lancet device by hand. Most needlestick accidents have occurred during recapping of a needle after a phlebotomy. Injuries also can occur to housekeeping personnel when contaminated sharps are left on a bed, concealed in linen, or disposed of improperly in a waste receptacle. Most accidental disposal-related exposures can be eliminated by the use of sharps containers. To discard sharps, containers are closed and placed in the biohazard waste. A needlestick injury must be reported to the supervisor or other designated individual.

Issues Related to HBV, HIV, and HCV Transmission

Medical personnel must be aware that HBV and HIV are totally different viruses. Exposure to HIV is uncommon, but cases of occupational transmission to healthcare personnel with no other known high-risk factors have been documented. Although HIV is an unlikely work-related hazard, it cannot be underrated because it can be fatal. The most feared hazard of all, the transmission of HIV through occupational exposure, is among the least likely to occur, if proper safety practices are followed. The transmission of HBV can also be fatal and is more probable than transmission of HIV.

HBV can be present in extraordinarily high concentrations in blood, but HIV is usually found in lower concentrations. HBV may be stable in dried blood and blood products at 25°C for up to 7 days. HIV retains infectivity for more than 3 days in dried specimens at room temperature and for more than 1 week in an aqueous environment at room temperature.

HBV Vaccination

Before the advent of the hepatitis B vaccine, the leading occupationally acquired infection in healthcare workers was hepatitis B. Although the number of cases of hepatitis B in healthcare workers has sharply declined since hepatitis B vaccine became widely available in 1982, approximately 800 healthcare workers still become infected with HBV each year following occupational exposure. The likelihood of infection after exposure to blood infected with HBV or HIV depends on additional factors:

1. Concentration of HBV or HIV; viral concentration is higher for HBV than for HIV.
2. Presence of skin lesions or abrasions on the hands or exposed skin of the healthcare worker.
3. Immune status of the healthcare worker for HBV.

OSHA issued a federal standard in 1991 mandating employers to provide the hepatitis B vaccine to all employees who have or may have occupational exposure to blood or other potentially infective materials. The vaccine is to be offered at no expense to the employee, and if the employee refuses the vaccine, a declination form must be signed.